14 - 80 - ACNE VARIANTS AND ACNEIFORM ERUPTIONS Flashcards

Infantile acne presents at 3 to 6 months of age classically with open and closed comedones over the cheeks and chin. (Fig. 80-2). Papules, pustules, and nodules can also present on the face. Pitted scarring may occur even with relatively mild disease. Infantile acne is caused in part by the transient elevation of dehydroepiandrosterone (DHEA) produced by the immature adrenal gland. 4 Additionally, during the first 6 to 12 months of life, boys may also have an increased level of luteinizing hormone (LH) that stimulates testosterone production. Around 1 year of age, these hormone levels begin to stabilize until they surge again during adrenarche. As a result, infantile acne usually resolves around 1 to 2 years of age. Treatment generally consists of topical retinoids and benzoyl peroxide. Oral therapy with erythromycin, azithromycin, trimethoprim, or isotretinoin can be used in severe or refractory cases.
most severe form of acne and may occur with or without systemic symptoms
Acne fulminans (also known as acute febrile ulcerative acne)

The sudden appearance of inflammatory, tender, oozing, friable plaques with hemorrhagic crusts characterizes this extreme presentation. The lesions predominate on the chest and back (Fig. 80-3) and rapidly become ulcerative and heal with scarring. The disease is reported to occur primarily in teenage boys. Systemic symptoms are often present. The patients are febrile; have a leukocytosis of 10,000 to 30,000/mm 3 white blood cells; and usually have polyarthralgia, myalgia, hepatosplenomegaly, and anemia. Bone pain is common, especially at the clavicle and sternum. Radiologic examination may demonstrate lytic bone lesions. Occasionally, there is accompanying erythema nodosum. Although this disease is often classified with acne conglobata, there are basic differences. The onset of acne fulminans is more explosive; nodules and polymorphous comedones are less common; the face is not involved as frequently, and the neck is usually spared; ulcerative and crusted lesions are unique; and systemic symptoms are more common.
Systemic glucocorticoid therapy, along with intralesional glucocorticoids, is first-line treatment for acne fulminans. Systemic glucocorticoids (prednisone 0.5–1.0 mg/kg/day) are started before isotretinoin for 2 to 4 weeks, depending on the severity of systemic symptoms, and continued during the first few weeks to months of isotretinoin therapy. The initial dosing of isotretinoin should be quite low (0.1 mg/kg/day) during the initial weeks of therapy until the inflammation is controlled. 6 The daily dose of glucocorticoids should be slowly decreased as tolerated over weeks to months. Alternately, 0.5 mg/kg/day of isotretinoin started immediately with 10 mg of prednisolone three times daily has been recommended. 7 Dapsone in conjunction with isotretinoin has been reportedly beneficial in the treatment of acne fulminans associated with erythema nodosum. 8 Cyclosporine, anakinra, and tumor necrosis factor (TNF) inhibitors have also been used in difficult cases of acne fulminans.9-11
What is SAPHO SYNDROME
SAPHO syndrome is manifested by synovitis, acne, pustulosis, hyperostosis, and osteitis. It is predominantly associated with hyperostosis of the anterior chest, palmoplantar pustulosis, hidradenitis suppurativa, and acne fulminans. Its cause is unknown. Reported successful treatments for SAPHO syndrome include nonsteroidal antiinflammatory drugs, sulfasalazine, infliximab, adalimumab, methotrexate. 12 Paradoxically, worsening of SAPHO skin manifestations can be seen with anti-TNF agents. 13,14 The bisphosphonates are beneficial for treating the associated bone pain.
What are PAPA, PASH, AND PAPSH SYNDROME
PAPA (pyogenic arthritis, pyoderma gangrenosum and acne), PASH (pyoderma gangrenosum, acne and hidradenitis suppurativa) and PAPASH (pyogenic arthritis, acne, pyoderma gangrenosum and hidradenitis suppurativa) are a group of systemic autoinflammatory disorders resulting from dysregulation of the innate immune system and over production of interleukin (IL)-1. 16 Patients with these disorders have a variable combination of sterile neutrophilic skin lesions, including acne, pyogenic granuloma, and hidradenitis suppurativa, and pyogenic arthritis. They may also give a history of inflammatory bowel disease and pancytopenia after administration of sulfacontaining medications. Mutations in the protein serinethreonine phosphatase interacting protein (PSTPIP1) results in an increase in IL-1β production. 17 There have been reports of successful treatment with cyclosporine, dapsone, infliximab, and anakinra.18,19
an autosomal dominant disorder marked by synostoses of the cranium, vertebral bodies and hands and feet
Apert syndrome, also known as acrocephalosyndactyly
It is caused by a mutation in the gene encoding FGFR-2. These patients have a diffuse acneiform eruption that often involves the arms, buttocks, and thighs. It is typically very resistant to treatment, but excellent responses to isotretinoin have been reported. 55 Patients with Apert syndrome may also present with severe seborrhea, nail dystrophy, and cutaneous and ocular hypopigmentation.

The facial Afro-Caribbean eruption (FACE) is another variant of periorificial dermatitis characterized by uniform, granulomatous sarcoidal papules distributed over the typical periorificial areas. 60 (Fig. 80-6) Distinguishing features include involvement of the upper eyelids and helices of the ears. 61 Histology is similar to granulomatous perioral dermatitis.
neonatal acne occurs around what age?
It resolves spontaneously within how many months?
2 weeks of age and resolve spontaneously within 3 months
Infantile acne is caused in part by the transient elevation of what hormone ?
**dehydroepiandrosterone (DHEA) **produced by the immature adrenal gland
Infantile acne presents at what month?
3 to 6 months
Mid-childhood acne is defined as appearing between what ages?
1 and 7 years of age
any child with acne in mid-childhood should be evaluated for other signs of hyperandrogenism (pubic or axillary hair, testicular enlargement or breast development)
mixture of comedones, papules, pustules, nodules, abscesses, and scars arising in a more generalized pattern over the back, buttocks, chest, and, to a lesser extent, on the abdomen, shoulders, neck, face, upper arms, and thighs
Acne conglobata
Draining lesions discharge a foul-smelling serous, purulent, or mucoid material.
Subcutaneous dissection with the formation of multichanneled sinus tracts is common
management of acne conglobata
- The use of isotretinoin is highly effective in these patients.
- However, because severe flares may occur when isotretinoin is started, the initial dose should be 0.5 mg/kg/day or less, and systemic glucocorticoids are often required either before initiating isotretinoin therapy or as concomitant therapy.
- Systemic tetracyclines, intralesional glucocorticoids, systemic glucocorticoids, surgical debridement, surgical incision, and surgical excision may also be required to effectively control acne conglobata
most severe form of acne and may occur with or without systemic symptoms
Acne fulminans (also known as acute febrile ulcerative acne)
The sudden appearance of inflammatory, tender, oozing, friable plaques with hemorrhagic crusts characterizes this extreme presentation.
Acne fulminans (also known as acute febrile ulcerative acne)
- The lesions predominate on the chest and back and rapidly become ulcerative and heal with scarring.
- The disease is reported to occur primarily in teenage boys
symptoms associated with acne fulminans
- The patients are febrile;
- have a leukocytosis of 10,000 to 30,000/mm3 white blood cells; and
- usually have polyarthralgia, myalgia, hepatosplenomegaly, and anemia.
- Bone pain is common, especially at the clavicle and sternum.
- Radiologic examination may demonstrate **lytic bone lesions. **
- Occasionally, there is accompanying erythema nodosum.
difference of acne fulminans and acne conglobata
- The onset of acne fulminans is more explosive;
- nodules and polymorphous comedones are less common;
- the face is not involved as frequently, and
- the neck is usually spared;
- **ulcerative and crusted **lesions are unique; and
- systemic symptoms are more common
first-line treatment for acne fulminans
Systemic glucocorticoid therapy, along with intralesional glucocorticoids
- Systemic glucocorticoids **(prednisone 0.5–1.0 mg/kg/day) **are started before isotretinoin for 2 to 4 weeks, depending on the severity of systemic symptoms, and continued during the first few weeks to months of isotretinoin therapy
- The i**nitial dosing of isotretinoin **should be quite low **(0.1 mg/kg/day) **during the **initial weeks of therapy **until the inflammation is controlled
- The daily dose of glucocorticoids should be** slowly decreased as tolerated over weeks to months. **
- Alternately, 0.5 mg/kg/day of isotretinoin started immediately with 10 mg of prednisolone three times daily has been recommended
- Cyclosporine, anakinra, and tumor necrosis factor (TNF) inhibitors have also been used in difficult cases of acne fulminans
has been reportedly beneficial in the treatment of acne fulminans associated with erythema nodosum
Dapsone in conjunction with isotretinoin
An explosive flare of tender, oozing, friable plaques with hemorrhagic crusts occurs with or without associated systemic symptoms after initiation of isotretinoin therapy
ISOTRETINOIN-INDUCED ACNE FULMINANS
- The flaring typically arises within the first month of treatment but may occur later.
- Patients with severe inflammatory acne in particular are at risk
how can you prevent flaring of acne when initiating isotretinoin?
- Lower starting doses of **isotretinoin (0.3 to 0.5 mg/kg/day) **and the concomitant addition of systemic corticosteroids may prevent flaring.
- If isotretinoin-induced acne fulminans does occur, the isotretinoin dose should be lowered or discontinued and prednisone therapy immediately started, following the guidelines for the management of acne fulminans above.
SAPHO syndrome
synovitis, acne, pustulosis, hyperostosis, and osteitis
It is predominantly associated with hyperostosis of the anterior chest, palmoplantar pustulosis, hidradenitis suppurativa, and acne fulminans.
Reported successful treatments for SAPHO syndrome
nonsteroidal antiinflammatory drugs, sulfasalazine, infliximab, adalimumab, methotrexate
Paradoxically, worsening of SAPHO skin manifestations can be seen with what agents
anti-TNF agents
beneficial for treating the associated bone pain in SAPHO syndrome
bisphosphonates